Leading Russian Cancer Specialists Dr. Zyryanov and Dr. Oschepkov Performed the First Cesium Prostate Implants at Neftyanik Hospital in the City of Tyumen Richland, WA (January 13, 2015) – IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that Urologist Alexander Zyryanov M.D. Ph.D. and… Read more »
Shares of IsoRay Inc opened today at $1.56 and are currently trading down at $1.509. ISR has a 1-year high of $3.77 and a 1-year low of $0.58. The stock’s 50-day moving average is $1.60 and it’s 200-day moving average is $2.02.
On the ratings front, IsoRay Inc has been the subject of a number of recent research reports. In a report published on December 1, analyst Jason Kolbert from Maxim Group reiterated a Buy rating on ISR, with a price target of $5, which represents a potential upside of 220.5% from where the stock is currently trading.
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.